Document Detail


Ruxolitinib.
MedLine Citation:
PMID:  22293561     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
Authors:
Ruben A Mesa; Uma Yasothan; Peter Kirkpatrick
Publication Detail:
Type:  Journal Article     Date:  2012-02-01
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  11     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2012  
Date Detail:
Created Date:  2012-02-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  103-4     Citation Subset:  IM    
Affiliation:
Division of Hematology & Medical Oncology, Mayo Clinic, Scottsdale, Arizona 85259, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  (Mis)treating the pharmacogenetic incidentalome.
Next Document:  Targeting IAP proteins for therapeutic intervention in cancer.